Narlaprevir (Narlaprevir)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiviral drugs (excluding HIV)

Included in the formulation
  • Arlansa®
    pills inwards 
    R-PHARM, CJSC     Russia
    • АТХ:

    J.05.A.E.   Protease Inhibitors

    Pharmacodynamics:

    The protease inhibitor NS3 / 4A of the hepatitis C virus, involved in viral replication. The blockade of the viral protease leads to a disruption in the maturation of viral particles of the hepatitis C virus of genotypes 1a and 1b.

    Pharmacokinetics:

    After oral administration, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is reached after 4 hours. The connection with plasma proteins is 79%.

    Metabolism in the liver.

    The half-life is 4-4.7 hours. Elimination with feces.

    Indications:It is used for the treatment of chronic hepatitis C of genotype 1.
    ICD-10

    I.B15-B19.B18.2   Chronic viral hepatitis C

    Contraindications:Pregnancy and lactation, age under 18 years, individual intolerance.
    Carefully:Age over 65 years, severe renal failure.
    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and during lactation, as well as for men during pregnancy partners.

    Dosing and Administration:

    Inside, 600 mg 2 times a day with meals.

    The highest daily dose: 1200 mg.

    The highest single dose: 1200 mg.

    Side effects:

    Central and peripheral nervous system: faint.

    Circulatory system: peripheral edema.

    Hematopoietic system: anemia, lymphopenia, thrombocytopenia, and leukopenia.

    Respiratory system: shortness of breath.

    Digestive system: diarrheal phenomena, diarrhea.

    Endocrine system: hypothyroidism.

    Sense organs: rarely - retinopathy.

    Dermatological reactions: rash, photosensitivity reactions.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Rifampicin reduces the effectiveness of narlaprevir up to 90%.

    Ritonavir potentiates the action of narlaprevir.

    Simultaneous use with indinavir leads to hyperbilirubinemia.

    Reduces the effectiveness of saquinavir with simultaneous admission.

    Slows the metabolism of irinotecan, increasing its toxicity.

    Potentiates the action of lidocaine, amiodarone, quinidine, diltiazem.

    Strengthens the effect of warfarin, which can lead to bleeding.

    Absorption of the drug is significantly reduced when using antacids due to a decrease in the acidity of gastric juice.

    Proton pump inhibitors and histamine H blockers2-receptors reduce the concentration of narlaprevir in blood plasma, reducing the effectiveness of the drug.

    Reduces the effectiveness of hormonal contraceptives containing estradiol.

    Special instructions:If it is necessary to appoint with nifedipine, verapamil, felodipine, nicardipine, it is necessary to titrate the dose of calcium channel blockers under ECG control.
    Instructions
    Up